Close
Tickets available now! Join us on October 17 for the 2022 Annual Awards Event.

Inflation Reduction Act Fact Sheet Outlines Important Changes for 2023 and Beyond

Share on facebook
Share on twitter
Share on linkedin
Share on email
Medicare Part D

A new Centers for Medicare & Medicaid Services (CMS) fact sheet outlines key Inflation Reduction Act (IRA) Medicare changes and effective dates.

Key prescription drug affordability highlights include:

  • 2023 — Insulin will be limited to $35 for a month’s supply. This takes effect January 1 for insulin covered under Part D and July 1 for insulin covered as durable medical equipment under Part B.
  • 2024 — Low-income assistance will be expanded to people with income at or below 150% of the federal poverty level.
  • 2025 — Part D enrollees will have their out-of-pocket drug costs capped at $2,000. They will also have the option to pay these costs in monthly amounts rather than all at once.

CMS also explains the IRA’s Part D structural changes:

  • 2024 — People who reach the Part D catastrophic phase will no longer have to pay cost-sharing.
  • 2025 — The Manufacturer Discount Program in Medicare Part D will replace the Medicare coverage gap discount program. In general, it will require drug manufacturers to pay a 10% discount on certain drugs in the initial coverage phase and a 20% discount in the catastrophic phase. Government reinsurance in the catastrophic phase will decrease from 80% to 20% for most brand-name drugs and from 80% to 40% for generics.

And the initial Medicare negotiation implementation timeline:

  • 2023 — CMS will announce the first 10 Part D drugs to be negotiated. They must be among the highest-spending, brand-name drugs that don’t have competition.
  • 2024 — CMS will publish the negotiated prices for these drugs.
  • 2025 — Medicare will negotiate prices for 15 more Part D drugs.
  • 2026 — The negotiated prices for the first 10 Part D drugs will take effect. This is the first year people with Medicare will see the direct impacts of negotiation. CMS will select another 15 drugs—under Part D or Part B—for negotiation.
  • 2027 — Negotiated prices for the 15 Part D drugs selected in 2025 will kick in. Each round is cumulative, adding to the total number of drugs with negotiated prices. CMS will announce 20 more Part B or Part D drugs for negotiation.

In subsequent years, CMS will continue negotiating prices, which will take effect two years later:

  • 2028 — Prices for the 15 drugs selected in 2026 will go into effect. CMS will announce 20 more Part B or Part D drugs for negotiation.
  • 2029 — Prices for the 20 drugs selected in 2027 will go into effect. CMS will announce 20 more Part B or Part D drugs for negotiation.
  • 2030 — Prices for the 20 drugs selected in 2028 will go into effect.
  • 2031 — Prices for the 20 drugs selected in 2029 will go into effect.

View the CMS timeline and frequently asked questions about these changes.

Read more about the Inflation Reduction Act.

The Latest
Most Read

Add Medicare to Your Inbox

Sign up to receive Medicare news, policy developments, and other useful updates from the Medicare Rights.